Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections

Ryan K. Shields; Brian A. Potoski; Ghady Haidar; Binghua Hao; Yohei Doi; Liang Chen; Ellen G. Press; Barry N. Kreiswirth; Cornelius J. Clancy; M. Hong Nguyen

doi:10.1093/cid/ciw636

Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections

Ryan K. Shields, Brian A. Potoski, Ghady Haidar, Binghua Hao, Yohei Doi, Liang Chen, Ellen G. Press, Barry N. Kreiswirth, Cornelius J. Clancy, M. Hong Nguyen

New Jersey Medical School (NJMS), Public Health Research Institute Center

Research output: Contribution to journal › Article › peer-review

351 Scopus citations

Abstract

Thirty-seven carbapenem-resistant Enterobacteriaceae (CRE)-infected patients were treated with ceftazidime-avibactam. Clinical success and survival rates at 30 days were 59% (22/37) and 76% (28/37), respectively. In 23% (5/22) of clinical successes, CRE infections recurred within 90 days. Microbiologic failure rate was 27% (10/37). Ceftazidime-avibactam resistance was detected in 30% (3/10) of microbiologic failures.

Original language	English (US)
Pages (from-to)	1615-1618
Number of pages	4
Journal	Clinical Infectious Diseases
Volume	63
Issue number	12
DOIs	https://doi.org/10.1093/cid/ciw636
State	Published - Dec 15 2016

All Science Journal Classification (ASJC) codes

Microbiology (medical)
Infectious Diseases

Keywords

Klebsiella pneumoniae carbapenemase
carbapenem-resistant Enterobacteriaceae
ceftazidime-avibactam resistance

Access to Document

10.1093/cid/ciw636

Cite this

Shields, R. K., Potoski, B. A., Haidar, G., Hao, B., Doi, Y., Chen, L., Press, E. G., Kreiswirth, B. N., Clancy, C. J., & Nguyen, M. H. (2016). Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections. Clinical Infectious Diseases, 63(12), 1615-1618. https://doi.org/10.1093/cid/ciw636

@article{b85b2c0b12184eac8308a91a3a28fee5,

title = "Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections",

abstract = "Thirty-seven carbapenem-resistant Enterobacteriaceae (CRE)-infected patients were treated with ceftazidime-avibactam. Clinical success and survival rates at 30 days were 59% (22/37) and 76% (28/37), respectively. In 23% (5/22) of clinical successes, CRE infections recurred within 90 days. Microbiologic failure rate was 27% (10/37). Ceftazidime-avibactam resistance was detected in 30% (3/10) of microbiologic failures.",

keywords = "Klebsiella pneumoniae carbapenemase, carbapenem-resistant Enterobacteriaceae, ceftazidime-avibactam resistance",

author = "Shields, {Ryan K.} and Potoski, {Brian A.} and Ghady Haidar and Binghua Hao and Yohei Doi and Liang Chen and Press, {Ellen G.} and Kreiswirth, {Barry N.} and Clancy, {Cornelius J.} and Nguyen, {M. Hong}",

year = "2016",

month = dec,

day = "15",

doi = "10.1093/cid/ciw636",

language = "English (US)",

volume = "63",

pages = "1615--1618",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "12",

}

Shields, RK, Potoski, BA, Haidar, G, Hao, B, Doi, Y, Chen, L, Press, EG, Kreiswirth, BN, Clancy, CJ & Nguyen, MH 2016, 'Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections', Clinical Infectious Diseases, vol. 63, no. 12, pp. 1615-1618. https://doi.org/10.1093/cid/ciw636

TY - JOUR

T1 - Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections

AU - Shields, Ryan K.

AU - Potoski, Brian A.

AU - Haidar, Ghady

AU - Hao, Binghua

AU - Doi, Yohei

AU - Chen, Liang

AU - Press, Ellen G.

AU - Kreiswirth, Barry N.

AU - Clancy, Cornelius J.

AU - Nguyen, M. Hong

PY - 2016/12/15

Y1 - 2016/12/15

N2 - Thirty-seven carbapenem-resistant Enterobacteriaceae (CRE)-infected patients were treated with ceftazidime-avibactam. Clinical success and survival rates at 30 days were 59% (22/37) and 76% (28/37), respectively. In 23% (5/22) of clinical successes, CRE infections recurred within 90 days. Microbiologic failure rate was 27% (10/37). Ceftazidime-avibactam resistance was detected in 30% (3/10) of microbiologic failures.

AB - Thirty-seven carbapenem-resistant Enterobacteriaceae (CRE)-infected patients were treated with ceftazidime-avibactam. Clinical success and survival rates at 30 days were 59% (22/37) and 76% (28/37), respectively. In 23% (5/22) of clinical successes, CRE infections recurred within 90 days. Microbiologic failure rate was 27% (10/37). Ceftazidime-avibactam resistance was detected in 30% (3/10) of microbiologic failures.

KW - Klebsiella pneumoniae carbapenemase

KW - carbapenem-resistant Enterobacteriaceae

KW - ceftazidime-avibactam resistance

UR - http://www.scopus.com/inward/record.url?scp=84995524184&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995524184&partnerID=8YFLogxK

U2 - 10.1093/cid/ciw636

DO - 10.1093/cid/ciw636

M3 - Article

C2 - 27624958

AN - SCOPUS:84995524184

SN - 1058-4838

VL - 63

SP - 1615

EP - 1618

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 12

ER -

Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections

Abstract

All Science Journal Classification (ASJC) codes

Keywords

Access to Document

Other files and links

Fingerprint

Cite this